Company intelligence / Profile preview

ForSight VISION4

South San Francisco, California, United Statesvisioniv.co.jp ↗

Ownership: Private
Development stage: Other

Overview

ForSight VISION4 developed a novel drug delivery platform designed to revolutionize treatment of retinal diseases by enabling sustained therapeutic release. The company was acquired by Roche in January 2017 before commercial launch or late-stage clinical results were published.

Therapeutic areas: Ophthalmology
Modalities: DeviceDrug delivery system
Industry: Therapeutic Medical Devices

Partnerships

No major partnerships disclosed prior to Roche acquisition; post-acquisition, integrated into Roche's ophthalmology R&D.

Beyond the preview

Go deeper on ForSight VISION4.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ForSight VISION4.

Explore the full profile